Replies to post #342286 on Option Millionaires

[jimmybob]

Seattle Genetics price target raised to $172 from $165 at Piper Sandler
Piper Sandler analyst Joseph Catanzaro raised the firm's price target on Seattle Genetics (SGEN) to $172 from $165 and keeps a Neutral rating on the shares after the company announced a collaboration pact with Merck (MRK) for both Tukysa and ladiratuzumab. Given his view that early data for ladiratuzumab in triple-negative breast cancer "hasn't been definitive," he sees the economics as "very favorable" to Seattle Genetics, Catanzaro tells investors. Noting Merck will also make a $1B equity investment, the analyst called the deal "a great strategic alliance" overall for Seattle Genetics

[Lucky_Charm$]

And now the question mark for Friday....I went to the bull side ;)